GNW: Santhera enters into agreement to acquire option from Idorsia for
exclusive sub-license of first-in-class dissociative steroid vamorolone
* Vamorolone in clinical development for Duchenne muscular dystrophy (DMD) by ReveraGen BioPharma Inc. - pivotal VISION-DMD Phase 2b study ongoing
* Vamorolone has the potential to become standard of care in young patients with DMD
* Positions Santhera as a leading company in the DMD space with two late-stage assets addressing the medical need of DMD patients at all disease stages
* Idorsia to become ...